ABSTRACT
INTRODUCTION
Hepatitis C virus (HCV) infection is a global prevailing public health problem, infecting an estimated 130 to 150 million people worldwide..
(1) Asians account for approximately 50% of individuals with HCV infection, primarily attributed to the overall population density of this region. (2) Among the more than 1.4 million deaths caused by viral hepatitis, approximately 60% occurred in Asia.
The prevalence of HCV infection varies depending on the geographical location of the country and its socioeconomic status, with less than 2% in developed countries and up to about 15% in developing nations. (2) This heterogeneity is further compounded by the several genotypes and subtypes of HCV that are found throughout the world. Global estimates on the prevalence of chronic hepatitis C (CHC) have been found to be as high as 90% or more in high-risk groups such as intravenous drug user (IVDU) populations. (4) The importance of understanding the epidemiology, including the distribution of HCV genotypes, is invaluable in establishing important public health policies and future healthcare plans.
Different treatment regimens exist for each genotypes, with varying response rates to conventional antiviral therapy. (5) Combination treatment with pegylated-interferon and ribavirin has been the conventional therapy for CHC until the recent arrival of direct-acting antiviral (DAA) agents.
Although DAA therapy has been shown to be efficacious, its cost remains an impediment for routine use. (6) The last HCV epidemiology study in the general population of Singapore was conducted in 1995, and the prevalence of HCV infection was found to be 0.37% among the blood donor population. (7) We hope to determine the prevalence of HCV infection among various populations and certain high-risk groups in Singapore, as well as the prevalence of the IL28B single nucleotide polymorphism, which has previously been shown to be linked with response to therapy. (8) Through this study, we hope to better understand how best to use our limited resources to treat CHC in these populations. The primary objective was to study the prevalence of anti-HCV antibody and the frequency of various HCV genotypes in the following populations: (a) blood donors (BD); (b) endstage renal disease patients on haemodialysis (HD); and (c) the IVDU population. The secondary objective was to study the prevalence of the IL28B human allele polymorphism within the highrisk populations to determine the possible treatment response to conventional versus newer, more expensive therapies for CHC.
METHODS
This was a retrospective cohort study where the sera of the HCV-positive individuals were retrospectively analysed. Due to the heterogeneous nature of the three populations studied, the methods used to assess prevalence in each group are discussed in detail below.
In the BD population, data regarding HCV prevalence was provided by the Health Science 
RESULTS
In the present study, the prevalence of HCV infection in the BD population was 0.058%. For the purpose of comparison with the four-year record of the HD population, the prevalence of HCV infection in the BD population from 2011 to 2014 was calculated and found to be 0.059% (Fig. 1) .
The demographic profile of the 42 available serum of HCV-positive BDs is listed in Table I . It is noteworthy that among the racial groups listed under "Others", seven out of the 11 individuals were of Burmese descent. HCV genotype analysis (Fig. 2) showed GT-3 (47.6%) to be the most predominant genotype among the HCV infected BDs, followed by GT-1b (16.7%) and GT-1a (14.3%). Interestingly, the four BDs with GT-6 infection were of Burmese descent. Table II shows the gender, racial and age breakdown of the HD population. A total of 1,575 patient records were retrieved from the renal database. Of these, 920 (58.4%) patients were male.
The majority of HD patients were of Chinese descent (n = 1,094, 69.5%), while those of other ethnicities made up the minority (n = 55, 3.5%). The mean age of individuals with anti-HCV AB+ and those with anti-HCV AB− was 51.7 ± 13.3 years and 60.9 ± 12.5 years, respectively. The prevalence of positive anti-HCV AB in the HD cohort (2011-2015) was 2.2% (n = 34, Table II ).
The four-year (2011-2014) prevalence of anti-HCV AB+ in the HD cohort was 2.14% (Fig. 1) . In contrast to the BD cohort, the HD cohort had a predominance of HCV-1 (32.4%) and HCV-3 (20.5%, Fig. 3 ) genotypes, respectively. HCV genotyping was not done in ten individuals with positive anti-HCV antibody for various reasons: four were deceased; three had spontaneous resolution of HCV infection; one was uncontactable; and two rejected the study. Table III shows the demographic information of the drug user population in our study. A total of 168 individuals attended the HCV screening across five halfway houses. Of these, 89 individuals volunteered to participate in the study, but only 83 were finally included and their data analysed -three were excluded due to poor venous access and three were excluded due to no prior drug abuse history as indicated through a screening questionnaire and interview. Out of these 83 drug users, 18 (21.7%) were found to be positive for HCV infection through screening. We further subdivided these individuals based on their method of drug use, namely via intravenous or non-intravenous route. Among 47 individuals who had ever used the intravenous route, 17 (36.2 %) were infected with HCV. 
) HCV: hepatitis C virus; IVDU: intravenous drug user
Genotyping could not be done in five of the drug users who were anti-HCV AB+ due to low viral load, i.e. RNA < 2,000 IU/mL (4/18) and insufficient serum (1/18). Of the 13 genotyped specimens, the majority were of GT-3 genotype (8/13) and the remaining were of GT-1a (4/13) and an indeterminate genotype (1/13). Two of the four who had HCV RNA < 2,000 IU/mL had previously been treated for CHC.
Anti-HCV AB+ blood samples collected from both the HD and IVDU populations were tested for the allelic distribution of IL28B allele rs12979860 (Table IV) . In total, 16 samples from the HD cohort and 18 samples from the IVDU cohort were evaluated for the IL28B allele. Of these, 29 (85.3%) samples showed a homozygous CC genotype. A binomial test of proportion was done, demonstrating a significantly higher proportion of CC genotype, as compared to the CT or TT genotype (p < 0.001). 
DISCUSSION
Previous studies of HCV prevalence in the Singapore general population have put the estimated percentage at around 0.5% in 1995. (7, (9) (10) (11) (12) The blood bank handled approximately 70,000 BDs in 2015. Current results from BDs have shown a decrease in the prevalence of HCV within Singapore to 0.059% with a decreasing trend between the years 2010 to 2014 (Fig. 1) . Analysis of retrieved anonymised blood samples tested for HCV by the blood bank showed a predominance of GT-3 genotype (47.6%), followed by GT-1 genotype (31.0%). These findings differ from those of past studies, which reported a predominance of GT-1 genotype in Singapore. (10) Of the current GT-3 infected BD population, Malay and Chinese individuals made up 50% and 25%, respectively (Fig.   2 ).
There is a wide range of HCV prevalence among HD patients worldwide, with a prevalence rate of about 10% in the United States (13) and 4% in Malaysia. (14) The HD population is one of the most at-risk populations for HCV infection. (15) In 2013, the National Registry of Disease, Singapore, reported a HCV infection prevalence rate of 3.7% in the HD population. (16) Our retrospective cohort study showed a prevalence rate of 2.2% (34/1,575) and a relatively stable annual prevalence rate throughout a five-year period (2009-2014). While our study was confined to HD patients who were on follow-up in one tertiary care hospital in Singapore, its large cohort size is able to provide insights on the prevalence of HCV infection among patients receiving HD in the Singapore community.
The lower prevalence of HCV infection in our HD populations, as compared to historical data, is consistent with the progressively decreasing HCV prevalence in our BD population.
Implementation and enforcement of infection control strategies, as well as increased blood transfusion screening, have been shown to result in a reduction in blood-borne infections such as HCV, (13, 17) and this has probably contributed to the decreasing prevalence in our HD population.
It is interesting to note that, while there is a change in the predominant HCV genotype of the HCV-infected BD population, that in the HD population had remained unchanged, with almost one-third of HCV infected HD patients showing a GT-1 genotype. Nonetheless, GT-3 infection appears to be increasing in the HD populations, as in the BD population.
In 2015, there were 3,343 drug arrests in Singapore. (18) It has been estimated that the prevalence of HCV infection among IVDUs in Southeast Asia is 60%-90%. (4) The role of needle sharing is a known risk factor and cause of HCV transmission among IVDU. (4) In the current study, almost all who tested positive for HCV infection in the drug abuse cohort had a history of intravenous drug use, yielding a 36.2% HCV prevalence rate, This is comparable to an earlier Singapore study that reported a HCV prevalence rate of 42.5% among those with prior history of intravenous drug use. (19) It is possible that our study could have underestimated the scale of the problem, as it was a short study with a small sample size and participation for HCV screening was offered on a voluntary basis, with a participation rate of 52.9% (89/168). Nonetheless, the genotypes found in our HCV-infected IVDU population were exclusively GT-1a and GT-3, with a predominance of the latter, which was similar to other studies. (20) As a secondary objective of our study, we looked at the frequency of IL28B rs12979860 allele in our HCV-infected HD and IVDU populations. Our results showed that there was a predominance (85.3% overall) of the favourable CC allele in these populations. Given our findings and the prohibitive cost of DAA agents, and keeping in mind that IL28B SNP is highly associated with increased sustained viral response following conventional PEG-IFN+RBV combination therapy for CHC, (8, (21) (22) (23) (24) it would seem reasonable to consider IL28B genotyping a priority, with the view of using PEG-IFN+RBV combination therapy as a first-line treatment for CHC, when appropriate, for a substantial proportion of the HCV-infected population in Singapore. Thus, the costly DAA agents can be reserved for the minority who have contraindications to, or poor predictive factors for sustained viral response following, PEG-IFN+RBV combination therapy.
This is particularly relevant to those with GT-3 HCV infection, such as the majority of the IVDU population, in which the choice of DAA agents is limited.
Our HD database was chosen due to its accessibility. However, this being a population followed up by a single public institution -albeit receiving haemodialysis from different HD centres in our wider Singapore community -has its limitations. Furthermore, our dataset did not allow us to calculate the length of time between the commencement of HD to the time of diagnosis of HCV infection. Future studies could explore the relationships between the risk of HCV infection and the length of time a patient has been on HD in the Singapore context. Our IVDU data was also limited by its small sample size of 47 individuals. This would account for the difference in significant values seen when comparing between unadjusted and adjusted odds ratios.
Similar to many developed nations, with increased blood surveillance and more widespread public awareness, the prevalence of HCV infection in both the BD and HD populations has dropped (0.059% and 2.2%, respectively), as compared to historical data. However, more work 
